GlassScriptPhysician profile
Tim Quoc Tran
NPI 1497032528
$4,177.64
in general payments reported to CMS, 2019-2025
27 companies · $895 in 2025
The $895 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $449 · 2022: $981 · 2023: $796 · 2024: $1,057 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $822.70 | 2021-2025 | Confirm Rx, Jot Dx, Proclaim |
| Amgen INC. | $773.30 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $459.23 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $439.63 | 2022-2025 | Verquvo |
| Boston Scientific Corporation | $280.72 | 2022-2023 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.96 | 2021-2025 | Jardiance |
| Heartflow, INC. | $149.28 | 2024-2025 | |
| Esperion Therapeutics, INC. | $144.94 | 2021-2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $105.88 | 2021-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $105.19 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $104.10 | 2021-2024 | Farxiga |
| Daiichi Sankyo INC. | $90.68 | 2023-2024 | Injectafer |
| Atricure, INC. | $83.31 | 2022 | |
| Inspire Medical Systems, INC. | $71.50 | 2025 | Inspire |
| Cleerly, INC. | $67.18 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $45.82 | 2024-2025 | Ozempic, Rybelsus |
| Cashflow Solutions, LLC | $40.15 | 2023-2025 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Impulse Dynamics (USA) INC. | $29.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.71 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.60 | 2021-2024 | Lifevest |
| Medicomp INC | $21.86 | 2021 | |
| Teleflex LLC | $16.72 | 2023 | Turnpike |
| Medtronic, INC. | $16.54 | 2025 | Linq II |
| Lexicon Pharmaceuticals, INC. | $16.18 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $15.36 | 2023 | |
| Vivaquant INC, Dba Rhythm Express | $13.60 | 2025 | Rhythm Express |
| Tactile Systems Technology INC | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.